Curacle Co. Ltd. (365270.KQ) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · South Korea
Curacle Co. Ltd. financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 1.63 bn KRW | 7.10 m KRW |
| Gross profit | 1.63 bn KRW | 7.10 m KRW |
| Operating income | -12.64 bn KRW | -16.50 bn KRW |
| EBIT | -12.43 bn KRW | -16.52 bn KRW |
| Net income | -14.89 bn KRW | -18.11 bn KRW |
| Diluted EPS – continuing operations | -912.17 KRW | -862.14 KRW |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Curacle Co. Ltd.
curacle co.,ltd., a bio-venture business, engages in the research and development of drugs for intractable vascular and metabolic diseases due to aging. The company's products in pipeline include CU06, a next-generation oral therapy, which completed phase 2a clinical trial for the treatment of diabetic macular edema; CU01, which completed Phase 2b clinical trial for Nrf2 activation and inhibition of TGF- ß/Smad signaling; MT-101, a fully humanized Tie2 agonist antibody for the treatment of renal diseases; and MT-103, a bispecific antibody combining Tie2 agonist and anti-VEGF functions for the treatment of wAMD. It also develops MT-105 for the treatment of irritable bowel diseases; MT-201, a non-bleeding anti-thrombotic antibody targeting PD-X; MT-202, a dual-mechanism therapy combining PD-X inhibition and Tie2 agonism for the treatment of acute ischemic stroke and heart failure with preserved ejection fraction; CU71, a next-generation neurovascular stabilizer for the treatment of alzheimer's disease; and CP01-R01, a first oral endothelial stabilizer"based candidate for companion animal CKD therapy. In addition, the company develops SOLVADYS, proprietary oral small-molecule platform for the treatment of endothelial dysfunction; and EAGLES, a flagship platform of Maptics for next-generation biologics. curacle co.,ltd. was incorporated in 2016 and is headquartered in Seoul, South Korea.
More stocks
- Sukgyung AT Co. Ltd. (357550.KQ)
- Eagle Cold Storage Enterprise Co Ltd (8905.TWO)
- YoungQin International Co (2755.TWO)
- Nightingale Health Oyj B (HEALTH.HE)
- Gordon Auto Body Parts Co Ltd (1524.TW)
- AirBoss of America Corp. (BOS.TO)
- Basso Industry Corp (1527.TW)
- Kao Fong Machinery Co Ltd (4510.TWO)
- Bank Net Indonesia Syariah Tbk PT (BANK.JK)
- PT Estee Gold Feet Tbk (EURO.JK)
- Bitcoin Group (ADE.DE)
- Cullman Bancorp, Inc. /MD/ (CULL)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.